Nurix Therapeutics's EBIT per Share for the
three
months ended in Aug. 2024 was $-0.75.
Its EBIT per Share for the trailing twelve months (TTM) ended in Aug. 2024 was $-3.18.
During the past 3 years, the average EBIT per Share Growth Rate was 11.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -37.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Nurix Therapeutics's EBIT per Share or its related term are showing as below:
NRIX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -65.6 Med: -52.3 Max: 11.7
Current: 11.7
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Nurix Therapeutics was 11.70% per year. The lowest was -65.60% per year. And the median was -52.30% per year.
NRIX's 3-Year EBIT Growth Rate is ranked better than 62.18% of 1248
companies
in the Biotechnology industry
Industry Median: 2.8
vs NRIX: 11.70
The historical data trend for Nurix Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nurix Therapeutics (NAS:NRIX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Nurix Therapeutics EBIT per Share Related Terms
Thank you for viewing the detailed overview of Nurix Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NRIX has been successfully added to your 